Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Protein Effect||no effect|
|Gene Variant Descriptions||SRC amplification indicates an increased number of copies of the SRC gene. However, the mechanism causing the increase is unspecified.|
|Associated Drug Resistance|
|Molecular Profile||Protein Effect||Treatment Approaches|
|SRC amp||no effect|
|ROS1 fusion ERBB2 amp NOTCH1 amp SRC amp STK11 amp|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|SRC amp||lung non-small cell carcinoma||sensitive||Derazantinib||Case Reports/Case Series||Actionable||In a Phase I trial, Derazantinib (ARQ 087) treatment resulted in 25% tumor reduction and stable disease for 36 weeks in a squamous non-small cell lung carcinoma patient harboring SRC amplification (PMID: 28972963; NCT01752920).||28972963 detail...|
|ROS1 fusion ERBB2 amp NOTCH1 amp SRC amp STK11 amp||lung non-small cell carcinoma||predicted - resistant||Crizotinib||Case Reports/Case Series||Actionable||In a clinical study, a non-small cell lung carcinoma patient harboring a ROS1 fusion treated with Xalkori (crizotinib) responded, but eventually progressed, and was subsequently found to harbor presumed resistance alterations, including amplification of SRC, ERBB2 (HER2), STK11, and NOTCH1 (PMID: 29636358).||29636358|